Combinations Comprising Brexpiprazole Or A Salt Thereof And A Second Drug For Use In The Treatment Of A Cns Disorder
Patent No. EP2694043 (titled "Combinations Comprising Brexpiprazole Or A Salt Thereof And A Second Drug For Use In The Treatment Of A Cns Disorder") was filed by Otsuka Pharmaceutical on Apr 4, 2012. The application was issued on Nov 1, 2017.
Patent Summary
Combining the drug 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (Compound (I)) with selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) to improve antidepressant efficacy and reduce side effects compared to monotherapy with either drug. The combination targets multiple neurotransmitter systems for more comprehensive antidepressant action. It also enables lower dosing frequency due to sustained release properties of Compound (I).
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP2694043
- Application Number
- EP12719460A
- Filing Date
- Apr 4, 2012
- Status
- Revoked
- Feb 21, 2020
- Publication Date
- Nov 1, 2017
- External Links
- Slate, Register , Google Patents